Hear Sascha D. W. Stave present a study that investigates patient preferences in atopic dermatitis treatment. Results show that safety is the top priority for patients, with many favoring treatments with fewer side effects, even if they take longer to show results. The study underscores the need for clinicians to emphasize safety in treatment discussions and for pharmaceutical companies to develop safer treatment options. 🔗 Read more about EADV 2024 here: https://lnkd.in/dxiqK8DT #AtopicDermatitis #Treatment #PatientPreferences
Dermatologi NO’s Post
More Relevant Posts
-
Hear Sascha D. W. Stave present a study that investigates patient preferences in atopic dermatitis treatment. Results show that safety is the top priority for patients, with many favoring treatments with fewer side effects, even if they take longer to show results. The study underscores the need for clinicians to emphasize safety in treatment discussions and for pharmaceutical companies to develop safer treatment options. 🔗 Read more about EADV 2024 here: https://lnkd.in/dsqhiFvs #AtopicDermatitis #Treatment #PatientPreferences
Safety Is One of the Main Drivers for Atopic Dermatitis Patient Preferences of Treatment
https://bpno.fi
-
Hear Sascha D. W. Stave present a study that investigates patient preferences in atopic dermatitis treatment. Results show that safety is the top priority for patients, with many favoring treatments with fewer side effects, even if they take longer to show results. The study underscores the need for clinicians to emphasize safety in treatment discussions and for pharmaceutical companies to develop safer treatment options. 🔗 Read more about EADV 2024 here: https://lnkd.in/dBxhEVh3 #AtopicDermatitis #Treatment #PatientPreferences
Safety Is One of the Main Drivers for Atopic Dermatitis Patient Preferences of Treatment
https://bpno.se
-
Hear Sascha Stave present a study that investigates patient preferences in atopic dermatitis treatment. Results show that safety is the top priority for patients, with many favoring treatments with fewer side effects, even if they take longer to show results. The study underscores the need for clinicians to emphasize safety in treatment discussions and for pharmaceutical companies to develop safer treatment options. 🔗 Read more about EADV 2024 here: https://lnkd.in/dvfjqe7f #AtopicDermatitis #Treatment #PatientPreferences
Safety Is One of the Main Drivers for Atopic Dermatitis Patient Preferences of Treatment
https://bpno.dk
-
🚀 Continuing Your Pharma Education: Proton Pump Inhibitors Explained 🏥 Our latest article covers Proton Pump Inhibitors (PPIs), from their history and mechanism to indications and top formulas. A must-read for newcomers in the pharmaceutical industry! #ProtonPumpInhibitors #PharmaEducation #GERD #PepticUlcers #AcidSuppression #MedicalKnowledge #PharmaceuticalIndustry #HealthCare #MedicalRepresentative #PharmaColleagues #Health #MedicalStudent #HealthTips Read the full article now! 👇
Proton Pump Inhibitors: History, Mechanism and Clinical Use
healthhintswithme.blogspot.com
-
Drug-Coated Balloon for In-Stent Restenosis Treatment by Boston Scientific Gets from FDA Green Light Boston Scientific has received FDA approval for its drug-coated balloon to treat in-stent restenosis, a condition where a stented artery narrows again due to plaque buildup or scar tissue. This approval is significant because coronary artery disease (CAD) remains a leading cause of death worldwide, and current treatment options for in-stent restenosis have limitations. The Agent balloon, coated with paclitaxel, demonstrated effectiveness in a study and is expected to become a significant player in the global market, potentially worth $500 million. The approval marks a significant advancement in treating in-stent restenosis and offers new hope for patients. For more details please click the link! https://lnkd.in/dARU6_p4 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
Drug-Coated Balloon for In-Stent Restenosis Treatment by Boston Scientific Gets from FDA Green Light
-
We're thrilled to invite you to our upcoming webinar: 'Benefits of Silicone-oil-free Syringe Systems.’ Our webinar will offer an in-depth look at how we have meticulously designed our prefilled syringe portfolio for ophthalmology to align with the rigorous standards of this specialized therapeutic field. In line with our commitment to excellence and the evolving landscape of drug technologies, we are proud to unveil our comprehensive prefilled silicone-oil-free syringe systems. Collaborating closely with our pharmaceutical partners, we're dedicated to advancing patient care and well-being. We have eliminated free silicone oil from the components of our prefilled syringe systems. This proactive measure not only mitigates the risk of drug interaction during storage but also minimizes potential post-injection risks to patients, ensuring unrivaled functionality in the market. Learn more about our speakers: Bernd Zeiß Zeiss and Maximilian Vogl Registration: https://lnkd.in/e6An8DF7 #innovatingforabetterlife #webinar #syringes #pharma #biotech #drugdelivery
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> FDA is poised to pull Ocaliva as adcomm documents question post-approval study results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare
FDA is poised to pull Ocaliva as adcomm documents question post-approval study results
endpts.com
-
SCHEDULING MEETINGS NOW! Who will be attending Patients as Partners Conference on March 20-22, 2024 in Philadelphia? Comment below! Firma Clinical Research #firmaclinicalresearch #clinicalresearch #clinicaltrials #hometrialservices #dct #dataservices #hometrial #pharmaceutical #centralpharmacy #blooddraws #samplecollections #decentralizedtrials #CRO #patientcare #pharma #biotech #healthcare #patientexperience #drugtrials #drugdevelopment #lifescience #decentralizedclinicaltrials #hybridtrials #biopharma #clinicaloperations #clinops #CRA #businessdevelopment #phlebotomist
-
-
Inhalation's moving to Madison, and so am I!! Reach out to learn more about the amazing talent and equipment relocated from our Somerset location to our Madison site. From rapid drug absorption to ease of use for patients, there are many reasons to consider developing an inhaled medicine. With our expanded inhalation study capacity in the U.S. and U.K., you can explore new potentials for your pharmaceutical product, possibly extending its lifespan and patient reach. Learn more about our inhalation testing capabilities and book your study today: https://lnkd.in/dAp_AHHb #InhalationToxicology #InhalationMedicine #QuickStudyStarts
-
-
📢 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱: 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗡𝗲𝘄𝘀 𝗥𝗼𝘂𝗻𝗱𝘂𝗽 📢 4th Oct 2024 - Discover the latest advancements in the pharmaceutical industry with our daily news update. Our roundup includes crucial FDA designations, innovative drug developments, and impactful clinical trial outcomes analysis. Stay ahead and grow faster. #pharmanews #biopharma #fdaapprovals #clinicaltrials #drugdevelopment #pharmadaily #thelansis #Psoriasis #psoriaticarthritis #Crohnsdisease #ulcerativecolitis #Growthhormonedeficiency #GHD #DanonDisease #LongQTSyndrome #LQTS #Platinumresistanthighgradeserousovariancancer #HGSOC #Alexanderdisease #AxD
-
